Fennec Pharmaceuticals Stock Performance
FENC Stock | USD 9.09 0.09 0.98% |
The firm shows a Beta (market volatility) of 1.13, which means a somewhat significant risk relative to the market. Fennec Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Fennec Pharmaceuticals is expected to follow. Fennec Pharmaceuticals has an expected return of -0.0906%. Please make sure to confirm Fennec Pharmaceuticals maximum drawdown, daily balance of power, relative strength index, as well as the relationship between the skewness and day typical price , to decide if Fennec Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Fennec Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Fennec Pharmaceuticals is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
Five Day Return (0.66) | Year To Date Return (18.26) | Ten Year Return 194.17 | All Time Return 194.17 |
Last Split Factor 1:3 | Last Split Date 2014-09-05 |
1 | Fennec exceeded Craig-Hallums expectations with Norgine deal, stock PT raised | 03/19/2024 |
2 | Acquisition by Raykov Rosty of 29167 shares of Fennec Pharmaceuticals subject to Rule 16b-3 | 04/01/2024 |
3 | Fennec Pharmaceuticals CEO sells over 437k in company stock | 04/03/2024 |
4 | Disposition of 29700 shares by Raykov Rosty of Fennec Pharmaceuticals at 10.8932 subject to Rule 16b-3 | 04/04/2024 |
5 | Fennec Pharmaceuticals director sells shares worth 8,360 | 04/15/2024 |
6 | Disposition of 22222 shares by Adrian Haigh of Fennec Pharmaceuticals at 10.2776 subject to Rule 16b-3 | 04/16/2024 |
7 | Acquisition by Adrian Haigh of 22222 shares of Fennec Pharmaceuticals at 2.31 subject to Rule 16b-3 | 04/17/2024 |
8 | Disposition of 22222 shares by Adrian Haigh of Fennec Pharmaceuticals at 9.62 subject to Rule 16b-3 | 04/18/2024 |
9 | Fennec Pharmaceuticals COO sells over 400k in company stock | 04/22/2024 |
10 | Disposition of 22223 shares by Adrian Haigh of Fennec Pharmaceuticals at 2.31 subject to Rule 16b-3 | 04/26/2024 |
11 | Acquisition by Raykov Rosty of 2431 shares of Fennec Pharmaceuticals subject to Rule 16b-3 | 04/30/2024 |
12 | Disposition of 2431 shares by Raykov Rosty of Fennec Pharmaceuticals at 9.1123 subject to Rule 16b-3 | 05/01/2024 |
13 | Fennec Pharmaceuticals CEO Rosty Raykov sells shares worth over 22,000 | 05/02/2024 |
Begin Period Cash Flow | 23.8 M |
Fennec |
Fennec Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 979.00 in Fennec Pharmaceuticals on February 3, 2024 and sell it today you would lose (70.00) from holding Fennec Pharmaceuticals or give up 7.15% of portfolio value over 90 days. Fennec Pharmaceuticals is currently does not generate positive expected returns and assumes 2.4443% risk (volatility on return distribution) over the 90 days horizon. In different words, 21% of stocks are less volatile than Fennec, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Fennec Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fennec Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Fennec Pharmaceuticals, and traders can use it to determine the average amount a Fennec Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0371
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | FENC |
Estimated Market Risk
2.44 actual daily | 21 79% of assets are more volatile |
Expected Return
-0.09 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Fennec Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Fennec Pharmaceuticals by adding Fennec Pharmaceuticals to a well-diversified portfolio.
Fennec Pharmaceuticals Fundamentals Growth
Fennec Stock prices reflect investors' perceptions of the future prospects and financial health of Fennec Pharmaceuticals, and Fennec Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fennec Stock performance.
Return On Equity | -10.06 | ||||
Return On Asset | -0.3 | ||||
Profit Margin | (0.76) % | ||||
Operating Margin | (0.19) % | ||||
Current Valuation | 264.02 M | ||||
Shares Outstanding | 27.1 M | ||||
Price To Earning | (3.82) X | ||||
Price To Book | 84.82 X | ||||
Price To Sales | 11.80 X | ||||
Revenue | 21.64 M | ||||
Gross Profit | 1.45 M | ||||
EBITDA | (13.01 M) | ||||
Net Income | (16.34 M) | ||||
Cash And Equivalents | 14.91 M | ||||
Cash Per Share | 0.57 X | ||||
Total Debt | 29.58 M | ||||
Debt To Equity | 0.58 % | ||||
Current Ratio | 5.12 X | ||||
Book Value Per Share | (0.43) X | ||||
Cash Flow From Operations | (17.46 M) | ||||
Earnings Per Share | (0.60) X | ||||
Market Capitalization | 247.12 M | ||||
Total Asset | 26.73 M | ||||
Retained Earnings | (218.12 M) | ||||
Working Capital | 19.3 M | ||||
Current Asset | 7.88 M | ||||
Current Liabilities | 1.97 M | ||||
About Fennec Pharmaceuticals Performance
To evaluate Fennec Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Fennec Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Fennec Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Fennec Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Fennec's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for Next Year | ||
Days Of Inventory On Hand | 610.66 | 814.75 | |
Return On Tangible Assets | (0.61) | (0.64) | |
Return On Capital Employed | (0.68) | (0.64) | |
Return On Assets | (0.61) | (0.64) | |
Return On Equity | 1.41 | 1.48 |
Things to note about Fennec Pharmaceuticals performance evaluation
Checking the ongoing alerts about Fennec Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fennec Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Fennec Pharmaceuticals generated a negative expected return over the last 90 days | |
Fennec Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
The company reported the previous year's revenue of 21.64 M. Net Loss for the year was (16.34 M) with profit before overhead, payroll, taxes, and interest of 1.45 M. | |
Fennec Pharmaceuticals currently holds about 14.91 M in cash with (17.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.57. | |
Fennec Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
Roughly 55.0% of the company shares are owned by institutional investors | |
Latest headline from investing.com: Fennec Pharmaceuticals CEO Rosty Raykov sells shares worth over 22,000 |
- Analyzing Fennec Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fennec Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Fennec Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Fennec Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fennec Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Fennec Pharmaceuticals' stock. These opinions can provide insight into Fennec Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fennec Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Fennec Stock analysis
When running Fennec Pharmaceuticals' price analysis, check to measure Fennec Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fennec Pharmaceuticals is operating at the current time. Most of Fennec Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Fennec Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fennec Pharmaceuticals' price. Additionally, you may evaluate how the addition of Fennec Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is Fennec Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fennec Pharmaceuticals. If investors know Fennec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fennec Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.60) | Revenue Per Share 0.8 | Quarterly Revenue Growth 5.342 | Return On Assets (0.30) | Return On Equity (10.06) |
The market value of Fennec Pharmaceuticals is measured differently than its book value, which is the value of Fennec that is recorded on the company's balance sheet. Investors also form their own opinion of Fennec Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Fennec Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fennec Pharmaceuticals' market value can be influenced by many factors that don't directly affect Fennec Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fennec Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fennec Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fennec Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.